📰 DXCM: FDA Clears Dexcom's Stelo as First OTC Glucose Monitor for Children

News: Reuters

Ticker: DXCM | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

The FDA has cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children aged two and older who do not use insulin. This marks the first time an OTC continuous glucose monitor has been approved for pediatric use, significantly expanding Stelo's addressable market. The device was previously cleared for adults in March 2024. This regulatory expansion positions Dexcom as a leader in non-insulin dependent pediatric diabetes management, building on a strong quarter and recent positive G7 study results.

Further Research: 🤖 Wiseek AI Analysis | 📰 Original Article

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.